Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops,
manufactures, and markets specialty pharmaceutical products in China, today
announced that the Company has completed clinical trials for Candesartan, an
anti-hypertension drug, and submitted the generic drug production application
to the SFDA.
Analysis of the clinical trial results shows that Candesartan Cilexetil is
a prodrug of Candesartan. It is 10-fold stronger in effect than Losartan, has
good selectivity (Candesartan has much greater affinity (>10,000-fold) for the
AT1 receptor than for the AT2 receptor), and has long effective time (one
administration per day in low dosage). As a prodrug, it also enables smooth
release via an oral solution, which makes it an ideal hypertension drug.
Candesartan, the leading anti-hypertension drug, is an angiotensin II
receptor antagonist for which 2007 worldwide sales exceeded $2.5 billion.
Discovered and originally synthesized by Takeda Pharmaceutical Company Limited,
Candesartan was jointly developed by Takeda and AstraZeneca Pharmaceuticals
for the treatment of hypertension, chronic heart failure, and left ventricular
In China, nearly 60% of all urban adults aged 65 years and over suffer
from hypertension, and prevalence in urban areas is expected to reach 100
million by 2011. Candesartan is listed in the China's National (Medical)
Insurance Catalog ("NIC"), allowing patients to be reimbursed by the
China Pharma's CEO and president, Ms. Zhilin Li, commented, "We are
pleased to announce the satisfactory completion of clinical trials for
Candesartan, a multi-billion dollar revenue-generating drug, ahead of schedule.
Hypertension is a serious problem linked to an increased incidence of other
diseases, particularly brain edema, coronary heart disease and diabetes.
Candesartan is a well-established and well-tolerated anti-hypertension drug
with an excellent safety record and is known to be particularly suitable for
cardiovascular and diabetic patients."
Ms. Li continued, "According to the Chinese government, ninety percent of
China's citizens will be covered by a universal healthcare system by the end
of calendar 2010. Candesartan's presence in the NIC allows users to receive
reimbursement and will provide effective treatment for a high number of
Chinese patients whose medication needs are seriously unmet. We see great
potential in the target market and are excited to have an opportunity to
provide this excellent anti-hypertension drug to individuals suffering from
hypertension in China."
SOURCE China Pharma Holdings, Inc.